Expert Interview
Discussing Pliant Therapeutics’ PLN-74809 (Dual selective inhibitor of aVβ6/aVβ1) for treating Idiopathic pulmonary fibrosis
Ticker(s): PLRXA pulmonologist with experience in treating Idiopathic pulmonary fibrosis.
Please describe your practice as a clinician,how many patients with Idiopathic pulmonary fibrosis do you see on a yearly basis? Can you describe the standard of care, and take us through the most promising upcoming treatments?
Please tell us the details about the mechanism of action of PLN-74809 in treating Idiopathic pulmonary fibrosis? How does it compare to standard of care?
How does PLN-74809 differentiate from other treatments for Idiopathic pulmonary fibrosis?
Please discuss the clinical trials conducted to evaluate the efficacy of PLN-74809 in treating Idiopathic pulmonary fibrosis.
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
